Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0099rc5.5 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

CRH-stimulated oxytocin in patients with hypopituitarism and hypothalamic damage: A randomized, single-blind, crossover, placebo-controlled trial

Asla Roca Queralt , Garrido Sanchez Maite , Urgell Rull Eulalia , Terzan Molina Silvia , Santos Vives Alicia , Fernandez Miro Merce , Varghese Nimmy , Atila Cihan , Calabrese Anna , Biagetti Betina , Christ-Crain Mirjam , Eckert Anne , Webb Susan M , Lawson Elizabeth A , Aulinas Maso Ana

Introduction: Disruption of the hypothalamic/pituitary axes may lead to hypopituitarism. Anterior pituitary deficiencies (APD) and arginine-vasopressin deficiency (AVP-D) are well established and are treated with hormone replacement. Over the last decade, preliminary studies support the presence of an oxytocin (OXT)-deficient state that might be clinically relevant in patients with hypopituitarism and hypothalamic damage (HHD). Therefore, identifying a provocative test to diag...
0 shares

ea0090p811 | Late-Breaking | ECE2023

Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term thERapy of endogenous Cushing’s syndrome: preliminary results of the MOSKETEER study

Detomas Mario , Simeoli Chiara , Ceccato Filippo , Aulinas Maso Ana , Dolce Pasquale , Rubinstein German , Antonini Simone , Stelmachowska-Banaś Maria , Minnetti Marianna , Corsello Andrea , Dischinger Ulrich , Di Paola Nicola , Voltan Giacomo , Santos Vives Alicia , Braun Leah , Mazzarella Alessandro , DEUTSCHBEIN Timo , Lania Andrea , Isidori Andrea , Reincke Martin , Carla Scaroni , M Webb Susan , Pivonello Rosario , Fassnacht Martin , Altieri Barbara

Background: Steroid synthesis inhibitors, like metyrapone, osilodrostat, and ketoconazole are used as second-line treatment in all types of endogenous Cushing’s syndrome (CS). However, a direct comparison of these three drugs is missing. This study aimed to compare these drugs in the short-term therapy of CS.Design: Retrospective multicenter study involving 15 European centers.Methods: Patients with CS treated with metyrapone,...
5 shares

ea0099rc13.3 | Rapid Communications 13: Late Breaking | ECE2024

Comparison of metyrapone, osilodrostat and ketoconazole in the therapy of endogenous Cushing’s syndrome: The MOSKETEER study

Detomas Mario , Ceccato Filippo , Simeoli Chiara , Dolce Pasquale , Aulinas Maso Ana , Gilis-Januszewska Aleksandra , Parasiliti Caprino Mirko , Bassiony Mohamed , Stelmachowska-Banaś Maria , Ferrante Emanuele , Pittaway James , Rubinstein German , Hanzu Felicia A , Pmglisi Soraya , Corsello Andrea , Antonini Simone , Sambula Lana , Minnetti Marianna , Haberbosch Linus , Deutschbein Timo , Dischinger Ulrich , Voltan Giacomo , Di Paola Nicola , Santos Vives Alicia , Minasyan Mari , Giordano Roberta , Fell Vanessa , Cylke-Falkowska Karolina , Mangone Alessandra , Plowman Christina , Vega Arturo , Braun Leah , Mazzarella Alessandro , Locantore Pietro , Faggiano Antongiulio , Terzolo Massimo , Lania Andrea , Kastelan Darko , Isidori Andrea , Reincke Martin , Bancos Irina , Arvat Emanuela , Webb Susan M , Carla Scaroni , Pivonello Rosario , Fassnacht Martin , Altieri Barbara

Background: Metyrapone, osilodrostat, and ketoconazole are steroidogenesis inhibitors used as second-line treatment in endogenous Cushing’s syndrome (CS). However, a direct comparison of these three drmgs is missing.Objective: To compare the efficacy of the three drmgs after short-term therapy (≤12 weeks) for CS.Methods: Multicenter, real-life retrospective study involving 20 centers worldwide. Patients with CS treated w...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more